Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

• Abbreviations in rheumatology, 1901
• Aceclofenac, vascular cell adhesion molecule 1/very late activation antigen-mediated lymphocyte cell adhesion and, 1677
• Acne, oligoarthritis associated with pustulosis and, 1889
• Acquired immunodeficiency syndrome (AIDS). See Human immunodeficiency virus (HIV)
• Acronyms in rheumatology, 1901
• Activation markers
  • in Churg-Strauss syndrome, 445
  • in SSc, 327
• Activator protein 1 (AP-1), paclitaxel inhibition of expression of, 869
• Adduction moment, hyaluronan, and disease severity in knee OA, 1233
• Adhesion molecules activated human leukocyte cell, in monocytes and RA, 2221
  • αEβ7, in SLE, 1456
  • on human articular chondrocytes, 1296
  • in polyarteritis nodosa, 435
  • production in rheumatoid nodules, 1783
  • in rheumatoid synovitis, 1365
  • in Salmonella infection, 1054
  • in SSc, 327
  • at synovial level in RA, 185
  • vascular cell adhesion molecule 1/very late activation antigen-mediated lymphocyte cell adhesion and NSAIDs, 1677
• Adjuvant arthritis
  • AICARTase blockage by 7-hydroxymethotrexate in, 1407
  • DMH-11C and, 163
  • macrophage migration inhibitory factor in, 910
• Age and depressive symptoms in RA, 298
• Aggrecan
  • cartilage, G1 domain in RA, 1019
  • in cultured human chondrocytes, 274
  • -induced polyarteritis in BALB/c mice, 1007
• AICARTase blockage by 7-hydroxymethotrexate in adjuvant arthritis, 1407
• Alkaptonuria (ochronosis) and OA, 1895
• Alkylating drug therapy associated with myelodysplastic syndromes, 1493
• Alleles
  • C5, in collagen-induced arthritis in mice, 256
  • FcγRIIa, in SLE, 421
  • HLA, in poststreptococcal reactive arthritis, 1096
  • HLA class I, 1620
  • HLA class II, 927, 1620
  • HLA-DQ, 68
  • MICA, 68
  • polymorphic CYP17, in SLE, 940
  • tumor necrosis factor and HLA class II, in anti-topoisomerase I responders in SSc, 1306
  • tumor necrosis factor α promoter, 1489
• Allergic granulomatous angiitis. See Churg-Strauss syndrome (CSS)
• Allograft rejection, human cytomegalovirus and vasculopathy of, 10
• Amaurosis fugax in giant cell (temporal) arteritis, 26
• Amenorrhea, thalidomide in lupus and, 2273
• American College of Rheumatology (ACR)
  • aPL detection methods and criteria for SLE, 1326
  • criteria for RA improvement, examination of thresholds, 1564
  • criteria for RA response, validation of, 1845
  • president's address, 1711
  • winners of 1998 slide competition, 2106
• Amyloidosis
  • multiple myeloma-associated, and giant cell (temporal) arteritis, 1312
  • and serum apolipoprotein E4 in RA, 1328
• Angiogenesis in RA, 951
• Angiography in cerebral vasculitis, 2086
• Angiotensin-converting enzyme (ACE) in SSc renal crisis, 1613
• Ankylosing spondylitis (AS)
  • Bath Ankylosing Spondylitis Radiology Index (BASRI), 2263
  • cyclooxygenase isoforms in, 122
  • HLA-B27 in, 58, 1489
  • HLA-DR in, 460
  • immunologic analysis of peripheral joint disease in, 180
  • prevalence in United States, 778
  • reference centile charts for assessment of, 1119
  • susceptibility loci, genome-wide screen for, 588
  • tumor necrosis factor α and, 1489
  • in twins, 2085
• Anti-aminoacyl-transfer RNA synthetase antibodies, 1625
• Antibiotics in Lyme disease, 195
• Antibodies/autoantibodies. See names of specific antibodies
• Anticardiolipin antibodies (aCL)
  • and hemostasis, 1420
  • in antiphospholipid syndrome, 800, 1513, 1514
  • in giant cell (temporal) arteritis, 701
  • and human monoclonal autoantibodies, 1026, 1326
• Anticentromere antibodies (ACA) in SSc, 74
• Anticentrosomal antibodies, 551
• Anti-DEK antibodies, in SLE and sarcoidosis, 1505
• Anti-endothelial cell antibodies
  • and antiphospholipid antibodies, 1738
  • in Churg-Strauss syndrome, 445
• Anti-Fas antibodies, apoptosis and
  • in RA, 1
  • in SLE, 344
  • as therapy in experimental RA, 1251
• Antigen-induced arthritis (AIA)
  • interleukin-1 regulation of matrix metalloproteinase-induced neoepitopes in, 647
  • transdermal photodynamic therapy in, 525
• Antigen-presenting cells (APC), expanded splenic B1a, in NZM2410 lupus-prone mice, 1652
• Antigens/autoantigens
  • apoptosis and, 1152
  • Env/Tax proteins in HTLV-I and, 101
  • LE cell factor, 1446
  • in RA, immunoreceptor repertoire formation for, 1911
  • RA synovial, 92
  • Salmonella, transport of, 1054
  • snRNP, in SLE, 603
  • -specific antibody responses after immunizations in SLE, 1828
  • VLA on human articular chondrocytes, 1296
  • VLA/VCAM-1-mediated lymphocyte cell adhesion and NSAIDs, 1677
  • Yersinia, in reactive arthritis, 315, 855
• Anti-histone H1 antibodies, and LE cells, 1446
• Anti-interleukin-6 in collagen-induced arthritis, 2117
• Anti-interleukin-12 in RA, 306
• Antimalarial drug-induced aquagenic-type pruritus in lupus, 744
• Antineuronal antibodies in pathogenesis of neuropsychiatric SLE, 1819
• Antineutrophil cytoplasmic antibodies (ANCA)
  • arteritis of superior mesenteric artery and, 1701
  • -associated vasculitis and cyclophosphamide therapy, 1835
  • in Churg-Strauss syndrome, 445
  • clinical utility and pathogenetic role in autoimmune disease, 1521
  • in GCA, 1701
  • monitoring in rheumatology practice, 725
• Antinuclear antibodies in healthy individuals, 1513
• Antiphospholipid antibodies (aPL)
  • detection methods, and ACR criteria for SLE, 1326
  • endothelial cells and, 1738
  • and induction of endothelin 1 in APS, 800
  • in SLE, 205, 215
• Antiphospholipid syndrome (APS)
  • aCL and hemostasis in, 1420
  • endothelin 1 in, 800
  • experimental, ciprofloxacin in, 224
  • gallbladder ischemic necrosis in catastrophic, 1318
  • IgG2 aCL and thrombosis in, 1513
  • microvasculopathy in catastrophic, 751, 753
• Anti-reshaping human interleukin-6 monoclonal antibodies in RA treatment, 2014
• Anti-ribosomal P antibodies (anti-P)
  • masked, in healthy children, 33
  • in pathogenesis of neuropsychiatric SLE, 1819
• Anti-Ro/SSA and anti-La/SSB antibodies
  • and anti-tRNA in recurrent erythema, 1625
  • in Japanese subjects, 927
  • in salivary glands of SS patients, 2238
• Anti-Sm autoantibodies, cross-reactivity with ribosomal protein S10, 1040
• Anti-snRNP, 603
• Anti-Th/To antibodies, in SSc, 74
• Anti-topoisomerase I responders, HLA class II and tumor necrosis factor alleles in, 1306
  • in SSc, 74
• Anti-transfer RNA (anti-tRNA) antibodies, 1625
• Anti-transfer RNAHis (anti-tRNAHis) antibodies, in myositis, 1428
• Anti-tumor necrosis factor α (anti-TNFα) and cyclosporine in collagen-induced arthritis, 1806
  • Fas apoptosis signaling defect and, 139
  • and MTX in RA, 1552
  • in RA, 564
• AP-1 transcription factor in RA, 470
• Apolipoprotein E4 in RA with amyloidosis, 1328
• Apoptosis
  • anti-tumor necrosis factor effects on Fas, 139
  • autoantigens and, 1152
  • molecular characterization of CD95 signaling mutant and, 1047
  • in OA chondrocytes, 285, 1266, 1632
  • in RA, 1, 1251
  • in SLE, 205, 215, 344, 596, 823, 1241
  • in SS-like disease in mice, 2175
• Arteritis
  • large-vessel, associated with chronic active Epstein-Barr virus, 369
  • of superior mesenteric artery, 1701
• Arthralgia and cryoglobulinemia in HIV and hepatitis C, 740
• Arthritis prevalence in the United States, 778
• Arthropathy
  • camptodactyly-coxa vara-pericarditis syndrome, 730
  • in fibroblastic rheumatism, 379
• Arthroplasty, total joint, in RA, 1072
• Arthroscopy, measuring inflammation in RA synovial tissue, 663
• ATP and UTP stimulation of prostaglandin E2 in RA synovial cells, 246
• Autoimmune diseases
  • after allogeneic bone marrow transplantation, 453
  • autoantibodies to poly(ADP-ribose) polymerase in, 918
  • HLA class II genes and Ro/SSA and La/SSB in, 927
  • human cytomegalovirus and vasculopathy of, 10
  • inflammatory myopathy, 400
  • minocycline-induced, 563
  • procalcitonin as marker of infection in, 566
• Avocado/soybean unsaponifiables
  • efficacy in knee and hip OA, 81
  • in SSc, 1705
• Azathioprine (AZA)
  • and refractory myositis, 392
  • thiopurine methyltransferase toxicity in RA and, 1858
• Azithromycin, in oligoarthritis associated with acne and pustulosis, 1889